Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SML009
MIFTS: 57

Small Intestine Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Small Intestine Adenocarcinoma

About this section

MalaCards integrated aliases for Small Intestine Adenocarcinoma:

Name: Small Intestine Adenocarcinoma 12 15
Small Intestinal Adenocarcinoma 12 52 17
Adenocarcinoma of the Small Instestine 52 58
Adenocarcinoma of the Small Bowel 52 58
Adenocarcinoma of Small Instestine 52
Adenocarcinoma of Small Intestine 12
Adenocarcinoma of Small Bowel 52
Small Bowel Adenocarcinoma 52

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:4906
NCIt 49 C7888
SNOMED-CT 67 424440001
ICD10 via Orphanet 33 D01.4
UMLS via Orphanet 72 C0278803
Orphanet 58 ORPHA104075
UMLS 71 C0278803
Sources

Summaries for Small Intestine Adenocarcinoma

About this section
NIH Rare Diseases : 52 Small intestine adenocarcinoma is one type of small bowel cancer , usually occurring in the duodenum or jejunum, that begins in the gland cells . The small intestine is part of the body's digestive syste m, which also includes the esophagus, stomach, and large intestine. The exact cause is still unknown, but it may be due to DNA changes in the small intestine adenocarcinoma cells. The symptoms of small bowel tumors are often vague. The most common symptoms are pain in the belly (which may be the first symptom), weight loss, weakness, fatigue and low red blood cell counts (anemia ). The treatment and prognosis for small intestine cancer depends on its stage (tumor size and site) and the presence of metastases . For early stage cancer, surgery may be all that is needed. For more advanced cancer chemotherapy or radiation therapy may be required. Please visit the National Cancer Institute website for additional information: Small Intestine Cancer Treatment (PDQR)-Patient Version

MalaCards based summary : Small Intestine Adenocarcinoma, also known as small intestinal adenocarcinoma, is related to gastric tubular adenocarcinoma and tubular adenocarcinoma. An important gene associated with Small Intestine Adenocarcinoma is S100A4 (S100 Calcium Binding Protein A4), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Oxaliplatin and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include small intestine, liver and t cells, and related phenotypes are Decreased replication of vaccinia virus (VACV) and hematopoietic system

Disease Ontology : 12 A small intestine carcinoma that derives from epithelial cells of glandular origin.

Sources

Related Diseases for Small Intestine Adenocarcinoma

About this section

Diseases in the Large Intestine Adenocarcinoma family:

Small Intestine Adenocarcinoma

Diseases related to Small Intestine Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 229)
# Related Disease Score Top Affiliating Genes
1 gastric tubular adenocarcinoma 30.2 MUC6 MUC5AC
2 tubular adenocarcinoma 29.9 MUC5AC CTNNB1 CDX2
3 anal canal adenocarcinoma 29.9 MUC5AC CDX2
4 appendix adenocarcinoma 29.6 KRAS CDX2
5 teratoma 29.4 KRAS CTNNB1 CDX2
6 peutz-jeghers syndrome 29.3 SMAD4 MUC6 CTNNB1
7 jejunal adenocarcinoma 29.3 PMS2 MSH6 MLH1 CDX2
8 large intestine adenocarcinoma 29.1 SMAD4 KRAS CTNNB1
9 jejunal cancer 29.0 PMS2 MSH6 MSH2 MLH1 CDX2
10 cystic teratoma 29.0 MUC6 MUC5AC KRAS CDX2
11 mucinous adenocarcinoma 29.0 MUC5AC MLH1 KRAS CDX2
12 adenocarcinoma 28.9 SMAD4 MSH6 MSH2 MLH1 KRAS CTNNB1
13 neurofibromatosis 28.8 PMS2 MSH6 MSH2 MLH1 KRAS
14 duodenum adenocarcinoma 28.2 PMS2 MUC6 MUC5AC MSH6 MSH2 MLH1
15 colorectal adenocarcinoma 28.1 PMS2 MSH6 MSH2 MLH1 KRAS CTNNB1
16 signet ring cell adenocarcinoma 28.0 MUC6 MUC5AC MSH2 MLH1 KRAS CTNNB1
17 familial adenomatous polyposis 27.6 SMAD4 PMS2 MSH6 MSH2 MLH1 KRAS
18 lynch syndrome 27.6 SMAD4 PMS2 MSH6 MSH2 MLH1 KRAS
19 endometrial cancer 27.0 SMAD4 PMS2 MSH6 MSH2 MLH1 KRAS
20 adenoma 26.9 SMAD4 MUC6 MUC5AC MSH6 MSH2 MLH1
21 gastric cancer 26.9 SMAD4 S100A4 MUC6 MUC5AC MSH2 MLH1
22 small intestine cancer 25.6 SMAD4 S100A14 PMS2 MUC6 MUC5AC MSH6
23 familial colorectal cancer 10.4 MSH2 MLH1
24 attenuated familial adenomatous polyposis 10.4 MSH6 MSH2
25 atypical polypoid adenomyoma 10.3 MLH1 CTNNB1
26 adenomyoma 10.3 MLH1 CTNNB1
27 lower lip cancer 10.3 MSH2 MLH1
28 biliary papillomatosis 10.3 MUC6 MUC5AC
29 spindle cell intraocular melanoma 10.3 PMS2 MLH1
30 bile duct cystadenocarcinoma 10.3 MUC6 MUC5AC
31 anal fistula 10.2 MSH2 MLH1
32 chronic ethmoiditis 10.2 MUC6 MUC5AC
33 filamentary keratitis 10.2 MUC5AC CPS1
34 colorectal cancer, hereditary nonpolyposis, type 4 10.2 PMS2 MLH1
35 deficiency anemia 10.2
36 melanocytic nevus syndrome, congenital 10.2 MSH2 MLH1
37 polyposis syndrome, hereditary mixed, 1 10.2 MUC6 MSH2 MLH1
38 renal pelvis transitional cell carcinoma 10.2 MSH6 MSH2 MLH1
39 solid adenocarcinoma with mucin production 10.2 MUC6 MUC5AC
40 crohn's disease 10.2
41 autosomal dominant non-syndromic intellectual disability 8 10.2 MSH6 MSH2 MLH1
42 keratoacanthoma 10.2 MSH2 MLH1 CTNNB1
43 breast-ovarian cancer, familial 1 10.2 MSH6 MSH2 MLH1
44 gastritis, familial giant hypertrophic 10.2 MUC6 MUC5AC
45 iron deficiency anemia 10.2
46 ileus 10.2
47 alveolar soft part sarcoma 10.1 MSH2 MLH1 CTNNB1
48 skin benign neoplasm 10.1 MSH6 MSH2 MLH1
49 anal gland adenocarcinoma 10.1 MUC5AC CDX2
50 rare tumor 10.1

Graphical network of the top 20 diseases related to Small Intestine Adenocarcinoma:



Diseases related to Small Intestine Adenocarcinoma
Sources

Symptoms & Phenotypes for Small Intestine Adenocarcinoma

About this section

GenomeRNAi Phenotypes related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased replication of vaccinia virus (VACV) GR00362-A 8.32 KRAS

MGI Mouse Phenotypes related to Small Intestine Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.96 CPS1 CTNNB1 KRAS MLH1 MSH2 MSH6
2 digestive/alimentary MP:0005381 9.92 CDX2 CTNNB1 KRAS MLH1 MSH2 MUC5AC
3 immune system MP:0005387 9.9 CPS1 CTNNB1 KRAS MLH1 MSH2 MSH6
4 mortality/aging MP:0010768 9.73 CDX2 CPS1 CTNNB1 KRAS LCOR MLH1
5 neoplasm MP:0002006 9.28 CDX2 CTNNB1 KRAS MLH1 MSH2 MSH6
Sources

Drugs & Therapeutics for Small Intestine Adenocarcinoma

About this section

Drugs for Small Intestine Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 43805 6857599 5310940 9887054
2
Ondansetron Approved Phase 3 99614-02-5 4595
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
7
Fluorouracil Approved Phase 3 51-21-8 3385
8 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
9 Hormones Phase 3
10 Cola Phase 3
11 Antineoplastic Agents, Hormonal Phase 3
12 Gastrointestinal Agents Phase 3
13 Liver Extracts Phase 3
14 Neurotransmitter Agents Phase 3
15 Anti-Anxiety Agents Phase 3
16 Antiemetics Phase 3
17 Hormone Antagonists Phase 3
18 glucocorticoids Phase 3
19 Psychotropic Drugs Phase 3
20 Dermatologic Agents Phase 3
21 Anti-Inflammatory Agents Phase 3
22 Antipsychotic Agents Phase 3
23 Anesthetics Phase 3
24 Narcotics Phase 3
25 Analgesics Phase 3
26 Analgesics, Opioid Phase 3
27 Anesthetics, General Phase 3
28 Anesthetics, Intravenous Phase 3
29 Antimetabolites Phase 3
30
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
31
Bevacizumab Approved, Investigational Phase 2 216974-75-3
32
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
33
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
34
Floxuridine Approved Phase 2 50-91-9 5790
35
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
36
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
37
Hydroxyurea Approved Phase 2 127-07-1 3657
38
Lenograstim Approved, Investigational Phase 2 135968-09-1
39
Melphalan Approved Phase 2 148-82-3 460612 4053
40
Acetaminophen Approved Phase 2 103-90-2 1983
41
Pembrolizumab Approved Phase 2 1374853-91-4
42
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
43
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
44
leucovorin Approved Phase 2 58-05-9 6006 143
45
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
46
ramucirumab Approved, Investigational Phase 2 947687-13-0
47
Pancrelipase Approved, Investigational Phase 2 53608-75-6
48
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
50
Lexatumumab Investigational Phase 2 845816-02-6

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 Endoscopic Detection of Small Bowel Dysplasia and Cancer in Patients With Jejuna or Ileal Crohn Disease : Prospective Study in a Cohort of High Risk Patients Completed NCT01180452 Phase 4
3 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
4 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 BALLAD BELGIUM: A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma Recruiting NCT04257461 Phase 3 Fluoropyrimidine;Oxaliplatin
6 PRODIGE 33 - BALLAD - Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma Not yet recruiting NCT02502370 Phase 3 observation alone;LV5FU2;FOLFOX
7 A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
8 Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed NCT01208103 Phase 2 Capecitabine;Oxaliplatin
9 Phase II Study of Panitumumab in KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed NCT01202409 Phase 2 Panitumumab
10 Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
11 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
12 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
13 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
14 A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2 Capecitabine;Oxaliplatin
15 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
16 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
17 Pilot Study to Investigate the Safety and Efficacy of Avelumab Monotherapy in Patients With Advanced or Metastatic Adenocarcinoma of the Small Intestine Active, not recruiting NCT03000179 Phase 2 Avelumab
18 A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas Active, not recruiting NCT02949219 Phase 2
19 Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma Not yet recruiting NCT04205968 Phase 2 Fluorouracil;Irinotecan;Irinotecan Hydrochloride;Leucovorin;Leucovorin Calcium;Paclitaxel
20 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
21 Pilot Study of Gemcitabine and IORT/EBRT in Locally Advanced Upper Gastrointestinal Malignancies Completed NCT00544193 Phase 1 gemcitabine hydrochloride
22 Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer. Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
23 A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
24 Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies Completed NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
25 Pilot Study of Oxaliplatin in Combination With Capecitabine in Adult Cancer Patients Completed NCT00019773 Phase 1 capecitabine;oxaliplatin
26 A Phase I Dose-Escalating Study of Recombinant Human Interleukin-12 (NSC # 672423) Administered by Intraperitoneal Infusion in Refractory Advanced Stage Ovarian Cancer and Other Abdominal Carcinomatosis Completed NCT00003439 Phase 1
27 Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis, Associated With Mullerian and Gastrointestinal Carcinomas Completed NCT00003046 Phase 1
28 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
29 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
30 A Phase I Clinical Trial To Assess The Safety And Efficacy Of Intraperitoneal PV701 Administrations In Patients With Advanced Or Recurrent Malignancy Largely Confined To The Peritoneal Cavity Completed NCT00055705 Phase 1
31 A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
32 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
33 A Phase I Study of Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin in Patients With Advanced Cancer of the Digestive System Completed NCT00010023 Phase 1 capecitabine;cisplatin
34 Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles Completed NCT00049296 Phase 1 docetaxel;thalidomide
35 Prospective Randomized Comparison Between Axial- and Lateral-viewing Capsule Endoscopy Systems in Celiac Patients: a Pilot Study Unknown status NCT03095573
36 A Capsule Endoscopy and Double Balloon Enteroscopy Sequential Approach for Early Detection of Gastrointestinal Tumors in Celiac Disease: a Prospective Trial Unknown status NCT02325232
37 Visceral Lymphatic Mapping Project: A Pilot Study Completed NCT00489515
38 Improving Palliative Care for Patients With Cancer Completed NCT00253383
39 Study of Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma Recruiting NCT03800212 treatment for ampullary adenocarcinoma
40 Phenotyping of Small Bowel Adenocarcinoma Active, not recruiting NCT02976090

Search NIH Clinical Center for Small Intestine Adenocarcinoma

Sources

Genetic Tests for Small Intestine Adenocarcinoma

About this section
Sources

Anatomical Context for Small Intestine Adenocarcinoma

About this section

MalaCards organs/tissues related to Small Intestine Adenocarcinoma:

40
Small Intestine, Liver, T Cells, Colon, Endothelial, Lymph Node
Sources

Publications for Small Intestine Adenocarcinoma

About this section

Articles related to Small Intestine Adenocarcinoma:

(show top 50) (show all 108)
# Title Authors PMID Year
1
A convenient clinical nomogram for predicting the cancer-specific survival of individual patients with small-intestine adenocarcinoma. 61
32487033 2020
2
Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs. 61
32267594 2020
3
[A rare case of cystadenoma in the small intestine]. 61
32306027 2020
4
Prognostic implications of immune classification in a multicentre cohort of patients with small intestinal adenocarcinoma. 61
31685233 2020
5
Insurance status is related to overall survival in patients with small intestine adenocarcinoma: A population-based study. 61
31548047 2020
6
Prognostic Significance of Stromal and Intraepithelial Tumor-Infiltrating Lymphocytes in Small Intestinal Adenocarcinoma. 61
31576398 2020
7
Detection of the Bacteroides fragilis toxin gene in sheep with and without small intestinal adenocarcinoma. 61
31378159 2019
8
Celiac disease: a comprehensive current review. 61
31331324 2019
9
Assessment of the external validity of the AJCC 8th staging system for small intestinal adenocarcinoma: a time to reconsider the role of tumor location? 61
31183191 2019
10
DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma. 61
30381262 2019
11
Retrospective study of survival time and prognostic factors for dogs with small intestinal adenocarcinoma treated by tumor excision with or without adjuvant chemotherapy. 61
30605388 2019
12
Dual loss of USP10 and p14ARF protein expression is associated with poor prognosis in patients with small intestinal adenocarcinoma. 61
30375264 2018
13
[A Case of Intussusception in the Jejunum Due to Small Intestinal Adenocarcinoma]. 61
30237385 2018
14
Influence of marital status on small intestinal adenocarcinoma survival: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database. 61
30532589 2018
15
Pancreatic non-functioning neuroendocrine tumor: a new entity genetically related to Lynch syndrome. 61
29184699 2017
16
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma? 61
28821192 2017
17
Metastatic intestinal adenocarcinoma to a lymph node involved by follicular lymphoma: The importance of looking beyond the apparent. 61
28476376 2017
18
Lynch syndrome-related small intestinal adenocarcinomas. 61
28206961 2017
19
Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas. 61
27169755 2016
20
[A Case of Ileocecal Intussusception Due to Small Intestinal Adenocarcinoma]. 61
28133155 2016
21
Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. 61
26892442 2016
22
[A Case of Long-Term Survival in a Patient with Small Intestinal Adenocarcinoma with Peritoneal Dissemination]. 61
26809539 2016
23
Insulin-Like Growth Factor II mRNA-Binding Protein 3 (IMP3) as a Useful Immunohistochemical Marker for the Diagnosis of Adenocarcinoma of Small Intestine. 61
26855452 2015
24
Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma. 61
25710579 2015
25
[A Case of Small Bowel Cancer Treated with Laparoscopic Surgery]. 61
26805147 2015
26
[Four Cases of Primary Small Intestinal Cancer]. 61
26805145 2015
27
SMALL INTESTINAL ADENOCARCINOMA WITH CARCINOMATOSIS IN A SWIFT FOX (VULPES VELOX). 61
26352968 2015
28
Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. 61
25930983 2015
29
Lifestyle factors and small intestine adenocarcinoma risk: A systematic review and meta-analysis. 61
25736860 2015
30
Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine. 61
25759539 2015
31
Small bowel imaging in celiac disease. 61
25925931 2015
32
[A case of long-term survival of small intestinal adenocarcinoma treated by resection and chemotherapy]. 61
25731553 2014
33
Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. 61
24603585 2014
34
Notch3 signaling is associated with MUC5AC expression and favorable prognosis in patients with small intestinal adenocarcinomas. 61
24810798 2014
35
Recovering a stuck capsule … and discovering a rare small-intestinal adenocarcinoma. 61
24679662 2014
36
[A case report of primary adenocarcinoma of the small intestine with peritoneal dissemination treated with multidisciplinary therapy]. 61
25129097 2014
37
S100A4 expression is a prognostic indicator in small intestine adenocarcinoma. 61
24062356 2014
38
Coexistence of granulomatous enteric inflammation and neoplasia in an adult sheep. 61
23456963 2013
39
Epithelial-mesenchymal transition phenotype is associated with patient survival in small intestinal adenocarcinoma. 61
24018801 2013
40
Molecular alterations of EGFR in small intestinal adenocarcinoma. 61
23644682 2013
41
Small intestinal adenocarcinoma: rarely considered, often missed? 61
23412393 2013
42
Loss of S100A14 expression is associated with the progression of adenocarcinomas of the small intestine. 61
23038644 2013
43
Expression of PI3K, PTEN and Akt in small intestinal adenocarcinoma detected by quantum dots-based immunofluorescence technology. 61
24240591 2013
44
Genome-wide gene expression profile of jejunal pouch mucosa as a gastric substitute. 61
22281974 2012
45
[A case of primary adenocarcinoma of small intestine responding to XELOX chemotherapy and leading to a partial metabolic response]. 61
22584343 2012
46
[Expression of Bcl-w protein in human small intestinal adenocarcinoma and effect of Bcl-w siRNA on apoptosis in intestinal adenocarcinoma HuTu-80 cells]. 61
22780970 2012
47
Coeliac disease in endocrine diseases of autoimmune origin. 61
22744631 2012
48
Small bowel adenocarcinoma complicating coeliac disease: a report of three cases and the literature review. 61
23243535 2012
49
High susceptibility to zymbal gland and intestinal carcinogenesis in diabetic Otsuka long-evans Tokushima Fatty rats. 61
22319230 2011
50
[A case report of multiple adenocarcinoma in small intestine after total gastrectomy by Roux-en-Y re-construction]. 61
22202278 2011
Sources

Variations for Small Intestine Adenocarcinoma

About this section

Cosmic variations for Small Intestine Adenocarcinoma:

9 (show top 50) (show all 63667)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88261999 ZRSR2 small intestine,duodenum,carcinoma,adenocarcinoma c.611G>A p.S204N 23:15815730-15815730 24
2 COSM149332692 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.1691C>T p.A564V 16:72958455-72958455 24
3 COSM149265665 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.8576C>T p.T2859M 16:72794106-72794106 24
4 COSM91382445 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.35C>T p.P12L 11:32435311-32435311 24
5 COSM91384162 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.742G>T p.D248Y 11:32428524-32428524 24
6 COSM85193879 U2AF1 small intestine,duodenum,carcinoma,adenocarcinoma c.692C>T p.S231L 21:43093133-43093133 24
7 COSM87029034 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 24
8 COSM87035637 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3551C>A p.A1184E 16:2080318-2080318 24
9 COSM87910722 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.764T>G p.I255S 17:7674199-7674199 24
10 COSM88214070 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.1052A>G p.K351R 17:7670657-7670657 24
11 COSM95881577 TGFBR2 small intestine,jejunum,carcinoma,adenocarcinoma c.1352C>T p.A451V 3:30674127-30674127 24
12 COSM135127211 TGFBR1 small intestine,duodenum,carcinoma,adenocarcinoma c.1136C>A p.T379K 9:99144882-99144882 24
13 COSM133362486 TET2 small intestine,duodenum,carcinoma,adenocarcinoma c.1124A>G p.E375G 4:105235066-105235066 24
14 COSM96854676 TENT5C small intestine,jejunum,carcinoma,adenocarcinoma c.839A>G p.D280G 1:117623707-117623707 24
15 COSM92119395 SUZ12 small intestine,duodenum,carcinoma,adenocarcinoma c.1058C>A p.P353H 17:31988354-31988354 24
16 COSM90702438 STK11 small intestine,jejunum,carcinoma,adenocarcinoma c.719C>T p.S240L 19:1220702-1220702 24
17 COSM90692741 STK11 small intestine,duodenum,carcinoma,adenocarcinoma c.580G>A p.D194N 19:1220488-1220488 24
18 COSM88446919 STAT3 small intestine,duodenum,carcinoma,adenocarcinoma c.635A>G p.Q212R 17:42337773-42337773 24
19 COSM86765978 STAG2 small intestine,duodenum,carcinoma,adenocarcinoma c.3018T>G p.F1006L 23:124083514-124083514 24
20 COSM93989109 SRC small intestine,duodenum,carcinoma,adenocarcinoma c.1460C>T p.P487L 20:37403228-37403228 24
21 COSM99811711 SPEN small intestine,duodenum,carcinoma,adenocarcinoma c.617G>A p.R206H 1:15876414-15876414 24
22 COSM99817072 SPEN small intestine,duodenum,carcinoma,adenocarcinoma c.4586G>A p.R1529H 1:15930826-15930826 24
23 COSM88094779 SOX9 small intestine,duodenum,carcinoma,adenocarcinoma c.242T>C p.L81P 17:72121633-72121633 24
24 COSM84674599 SMO small intestine,duodenum,carcinoma,adenocarcinoma c.1571C>T p.A524V 7:129210467-129210467 24
25 COSM89655095 SMARCA4 small intestine,duodenum,carcinoma,adenocarcinoma c.2647G>T p.G883C 19:11021755-11021755 24
26 COSM91386108 SMAD4 small intestine,jejunum,carcinoma,adenocarcinoma c.1157G>T p.G386V 18:51067036-51067036 24
27 COSM91381918 SMAD4 small intestine,duodenum,carcinoma,adenocarcinoma c.1612G>A p.E538K 18:51078420-51078420 24
28 COSM91075705 SMAD3 small intestine,duodenum,carcinoma,adenocarcinoma c.772G>A p.D258N 15:67181354-67181354 24
29 COSM91075523 SMAD3 small intestine,duodenum,carcinoma,adenocarcinoma c.1027T>G p.F343V 15:67187382-67187382 24
30 COSM88340746 SMAD2 small intestine,duodenum,carcinoma,adenocarcinoma c.938T>C p.L313S 18:47848534-47848534 24
31 COSM88343804 SMAD2 small intestine,duodenum,carcinoma,adenocarcinoma c.1298G>A p.S433N 18:47841933-47841933 24
32 COSM92477893 SH2B3 small intestine,duodenum,carcinoma,adenocarcinoma c.616G>A p.A206T 12:111418761-111418761 24
33 COSM89629666 SF3B1 small intestine,jejunum,carcinoma,adenocarcinoma c.1226C>A p.P409Q 2:197408011-197408011 24
34 COSM88232879 RPTOR small intestine,duodenum,carcinoma,adenocarcinoma c.3104C>T p.T1035M 17:80945745-80945745 24
35 COSM88235706 RPTOR small intestine,duodenum,carcinoma,adenocarcinoma c.2875T>C p.F959L 17:80925436-80925436 24
36 COSM93209816 RPS6KA4 small intestine,duodenum,carcinoma,adenocarcinoma c.1355G>A p.R452H 11:64368724-64368724 24
37 COSM93211056 RPS6KA4 small intestine,jejunum,carcinoma,adenocarcinoma c.806C>T p.A269V 11:64361902-64361902 24
38 COSM93849209 ROS1 small intestine,duodenum,carcinoma,adenocarcinoma c.1289G>A p.G430D 6:117389820-117389820 24
39 COSM103194883 RHOA small intestine,duodenum,carcinoma,adenocarcinoma c.77G>A p.S26N 3:49375513-49375513 24
40 COSM86691927 REL small intestine,duodenum,carcinoma,adenocarcinoma c.323G>A p.R108Q 2:60901012-60901012 24
41 COSM144751875 RECQL4 small intestine,duodenum,carcinoma,adenocarcinoma c.1649C>T p.A550V 8:144514497-144514497 24
42 COSM85615141 RAF1 small intestine,jejunum,carcinoma,adenocarcinoma c.770C>T p.S257L 3:12604200-12604200 24
43 COSM85615128 RAF1 small intestine,jejunum,carcinoma,adenocarcinoma c.776C>T p.S259F 3:12604194-12604194 24
44 COSM96919619 RAD54L small intestine,duodenum,carcinoma,adenocarcinoma c.1181G>A p.R394Q 1:46272477-46272477 24
45 COSM100085588 RAD50 small intestine,duodenum,carcinoma,adenocarcinoma c.3836G>A p.R1279H 5:132642261-132642261 24
46 COSM84609043 RAD21 small intestine,duodenum,carcinoma,adenocarcinoma c.1642G>A p.D548N 8:116849008-116849008 24
47 COSM97007554 PTPRT small intestine,duodenum,carcinoma,adenocarcinoma c.4291A>G p.T1431A 20:42081920-42081920 24
48 COSM139869371 PTPRS small intestine,jejunum,carcinoma,adenocarcinoma c.5482G>A p.A1828T 19:5210474-5210474 24
49 COSM139869389 PTPRS small intestine,jejunum,carcinoma,adenocarcinoma c.2698A>G p.T900A 19:5223094-5223094 24
50 COSM139869403 PTPRS small intestine,jejunum,carcinoma,adenocarcinoma c.341G>T p.G114V 19:5273480-5273480 24

Copy number variations for Small Intestine Adenocarcinoma from CNVD:

7 (show all 22)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13776 1 1 39600000 Copy number LCK Small bowel adenocarcinoma
2 13777 1 1 39600000 Copy number MDS2 Small bowel adenocarcinoma
3 13778 1 1 39600000 Copy number PAX7 Small bowel adenocarcinoma
4 13779 1 1 39600000 Copy number PRDM16 Small bowel adenocarcinoma
5 13780 1 1 39600000 Copy number RPL22 Small bowel adenocarcinoma
6 13781 1 1 39600000 Copy number SDHB Small bowel adenocarcinoma
7 76578 13 32900000 93800000 Copy number LCP1 Small bowel adenocarcinoma
8 76579 13 32900000 93800000 Copy number LHFP Small bowel adenocarcinoma
9 76580 13 32900000 93800000 Copy number RB1 Small bowel adenocarcinoma
10 106872 17 1 6800000 Copy number USP6 Small bowel adenocarcinoma
11 180663 4 10900000 191273063 Copy number CHIC2 Small bowel adenocarcinoma
12 180664 4 10900000 191273063 Copy number FBXW7 Small bowel adenocarcinoma
13 180665 4 10900000 191273063 Copy number FIP1L1 Small bowel adenocarcinoma
14 180666 4 10900000 191273063 Copy number IL2 Small bowel adenocarcinoma
15 180667 4 10900000 191273063 Copy number KIT Small bowel adenocarcinoma
16 180668 4 10900000 191273063 Copy number PDGFRA Small bowel adenocarcinoma
17 180669 4 10900000 191273063 Copy number PHOX2B Small bowel adenocarcinoma
18 180670 4 10900000 191273063 Copy number RAP1GDS1 Small bowel adenocarcinoma
19 244962 9 1 51800000 Copy number FANCG Small bowel adenocarcinoma
20 244963 9 1 51800000 Copy number JAK2 Small bowel adenocarcinoma
21 244964 9 1 51800000 Copy number MLLT3 Small bowel adenocarcinoma
22 244965 9 1 51800000 Copy number PAX5 Small bowel adenocarcinoma
Sources

Expression for Small Intestine Adenocarcinoma

About this section
Search GEO for disease gene expression data for Small Intestine Adenocarcinoma.
Sources

Pathways for Small Intestine Adenocarcinoma

About this section

Pathways related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 36
Show member pathways
 12.59 SMAD4 MSH6 MSH2 MLH1 KRAS CTNNB1
2
Pathways in cancer 36
12.52 SMAD4 MSH6 MSH2 MLH1 KRAS CTNNB1
3
Gastric cancer 36
Show member pathways
 12.5 SMAD4 MLH1 KRAS CTNNB1 CDX2
4
Signaling pathways regulating pluripotency of stem cells 36
11.84 SMAD4 KRAS CTNNB1
5
Direct p53 effectors 1
11.79 PMS2 MSH2 MLH1
6
Integrated Breast Cancer Pathway 1
11.74 SMAD4 MSH6 MSH2 KRAS CTNNB1
7
DNA Damage Response (only ATM dependent) 1
11.71 SMAD4 KRAS CTNNB1
8
Mismatch repair 1 36 65
Show member pathways
 11.54 PMS2 MSH6 MSH2 MLH1
9
Platinum drug resistance 36
11.5 MSH6 MSH2 MLH1
10
Colorectal Cancer Metastasis 63
11.32 SMAD4 MSH6 MSH2 MLH1 KRAS CTNNB1
11
Extracellular vesicle-mediated signaling in recipient cells 1
11.06 SMAD4 KRAS CTNNB1
12
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 60
10.72 PMS2 MSH6 MSH2 MLH1
Sources

GO Terms for Small Intestine Adenocarcinoma

About this section

Cellular components related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MutLalpha complex GO:0032389 9.16 PMS2 MLH1
2 MutSalpha complex GO:0032301 8.96 MSH6 MSH2
3 mismatch repair complex GO:0032300 8.92 PMS2 MSH6 MSH2 MLH1

Biological processes related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 DNA repair GO:0006281 9.88 PMS2 MSH6 MSH2 MLH1
2 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.67 MUC6 MUC5AC KRAS
3 gastrulation with mouth forming second GO:0001702 9.57 SMAD4 CTNNB1
4 anterior/posterior axis specification GO:0009948 9.56 CTNNB1 CDX2
5 determination of adult lifespan GO:0008340 9.55 MSH6 MSH2
6 epithelial tube branching involved in lung morphogenesis GO:0060441 9.54 KRAS CTNNB1
7 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.54 MSH6 MSH2 MLH1
8 positive regulation of histone H3-K4 methylation GO:0051571 9.52 SMAD4 CTNNB1
9 negative regulation of DNA recombination GO:0045910 9.51 MSH6 MSH2
10 positive regulation of isotype switching to IgG isotypes GO:0048304 9.48 MSH2 MLH1
11 positive regulation of helicase activity GO:0051096 9.46 MSH6 MSH2
12 mismatch repair GO:0006298 9.46 PMS2 MSH6 MSH2 MLH1
13 positive regulation of isotype switching to IgA isotypes GO:0048298 9.43 MSH2 MLH1
14 isotype switching GO:0045190 9.43 MSH6 MSH2 MLH1
15 maintenance of DNA repeat elements GO:0043570 9.4 MSH6 MSH2
16 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.32 MSH2 MLH1
17 somatic recombination of immunoglobulin gene segments GO:0016447 9.13 MSH6 MSH2 MLH1
18 somatic hypermutation of immunoglobulin genes GO:0016446 8.92 PMS2 MSH6 MSH2 MLH1

Molecular functions related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.84 MSH6 MSH2 MLH1 CTNNB1
2 ATPase activity GO:0016887 9.76 PMS2 MSH6 MSH2 MLH1
3 chromatin binding GO:0003682 9.72 SMAD4 MSH6 MSH2 MLH1 CTNNB1
4 double-stranded DNA binding GO:0003690 9.7 MSH6 MSH2 CDX2
5 single-stranded DNA binding GO:0003697 9.67 PMS2 MSH2 MLH1
6 four-way junction DNA binding GO:0000400 9.51 MSH6 MSH2
7 I-SMAD binding GO:0070411 9.48 SMAD4 CTNNB1
8 MutSalpha complex binding GO:0032407 9.43 PMS2 MLH1
9 MutLalpha complex binding GO:0032405 9.4 MSH6 MSH2
10 oxidized purine DNA binding GO:0032357 9.37 MSH6 MSH2
11 single guanine insertion binding GO:0032142 9.26 MSH6 MSH2
12 single thymine insertion binding GO:0032143 9.16 MSH6 MSH2
13 guanine/thymine mispair binding GO:0032137 9.13 MSH6 MSH2 MLH1
14 mismatched DNA binding GO:0030983 8.92 PMS2 MSH6 MSH2 MLH1
Sources

Sources for Small Intestine Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....